Filtered By:
Specialty: Drugs & Pharmacology
Drug: Coumadin

This page shows you your search results in order of date. This is page number 16.

Order by Relevance | Date

Total 300 results found since Jan 2013.

An update on the pharmaceutical management of thrombosis.
Authors: Cosmi B Abstract INTRODUCTION: Anticoagulants such as heparins and vitamin K antagonists (VKA) are effective for thrombosis prevention and treatment, but are associated with the risk of bleeding and other limitations, spurring the search for improved drugs. AREAS COVERED: to evaluate the newer anticoagulants, focusing on those tested in phase III clinical trials such as direct oral anticoagulants (DOACs), antisense oligonucleotides (ASO) and warfarin analogues. DOACs such as dabigatran, rivaroxaban, apixaban and edoxaban are licensed for stroke prevention in atrial fibrillation and treatment of venous ...
Source: Expert Opinion on Pharmacotherapy - October 1, 2016 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Assessment of Web ‐based education resources informing patients about stroke prevention in atrial fibrillation
This study qualitatively assessed the information presented to patients in online resources about antithrombotic therapy for stroke prevention in AF.
Source: Journal of Clinical Pharmacy and Therapeutics - September 30, 2016 Category: Drugs & Pharmacology Authors: E. Pandya, B. V. Bajorek Tags: Original Article Source Type: research

New oral anticoagulants for stroke prevention in atrial fibrillation
Around 12,500 strokes are caused by atrial fibrillation (AF) in the UK each year, and 7,100 of these are preventable with appropriate anticoagulation. Four new oral anticoagulants (NOACs) are now available in the UK in addition to warfarin.
Source: The Pharmaceutical Journal - September 23, 2016 Category: Drugs & Pharmacology Source Type: research

Factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia
Conclusion Abrupt dabigatran discontinuation without an alternative oral anticoagulant increases the risk of thromboembolic events. As adverse drug events and renal impairment contribute substantially to the premature discontinuation of dabigatran, it is important to identify and monitor patients at risk to reduce dabigatran discontinuation rate especially during the first six months of dabigatran therapy.
Source: International Journal of Clinical Pharmacy - September 21, 2016 Category: Drugs & Pharmacology Source Type: research

Right Ventricular Dysfunction Complicates Time in Therapeutic Range in Heart Failure Patients Receiving Warfarin
Conclusions: The present study demonstrated that presence of RVD in HF increases the risk for poor anticoagulation.Pharmacology 2017;99:19-26
Source: Pharmacology - September 21, 2016 Category: Drugs & Pharmacology Source Type: research

Idarucizumab: Clinical Role of a Novel Reversal Agent for Dabigatran.
Authors: Teleb M, Salire K, Wardi M, Alkhateeb H, Said S, Mukherjee D Abstract Atrial fibrillation (AF), a common cardiac arrhythmia associated with increased risk of heart failure, thromboembolic phenomena and death, is a leading cause of hospitalization of adults. A major complication of atrial fibrillation is an increased risk of ischemic stroke leading to long-term disability and in severe cases, death. Historically, coumadin has been the drug of choice for chronic anticoagulation and stroke prevention in AF patients however, given the need for constant monitoring and multiple drug interactions, newer anticoagu...
Source: Cardiovascular and Hematological Disorders Drug Targets - August 3, 2016 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

A prospective study investigating the causes of warfarin under-utilization in Chinese patients
Conclusion Patients with CHA2DS2-VASc scores ≥1 who were admitted with NVAF were under prescribed warfarin, and 138 patients were not treated with either warfarin or other antithrombotic therapies. In conclusion, a more aggressive approach for stroke prevention in NVAF patients is required.
Source: International Journal of Clinical Pharmacy - August 2, 2016 Category: Drugs & Pharmacology Source Type: research

Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis
Conclusions Rivaroxaban is a valuable treatment option for patients with biological prostheses, repaired mitral valves, or a tubular aortic graft in order to prevent thromboembolic complications.
Source: Clinical Drug Investigation - July 10, 2016 Category: Drugs & Pharmacology Source Type: research

Utilization of antithrombotic therapy for stroke prevention in atrial fibrillation: a cross‐sectional baseline analysis in general practice
Conclusion: We found an encouraging improvement compared to previous studies in the utilisation of antithrombotic therapy for stroke prevention in AF within general practice. Warfarin is now utilised as the mainstay therapy, followed by aspirin, although the novel oral anticoagulants are entering the spectrum of therapies used. Consideration needs to be given to the potential impact of the newer agents and their scope of use. There has been an encouraging temporal improvement in the utilization of antithrombotic therapy for stroke prevention in AF within general practice. Anticoagulants (mostly warfarin) are now utilized ...
Source: Journal of Clinical Pharmacy and Therapeutics - June 23, 2016 Category: Drugs & Pharmacology Authors: B. Bajorek, P. J. Magin, S. Hilmer, I. Krass Tags: Original Article Source Type: research

Utilization of antithrombotic therapy for stroke prevention in atrial fibrillation: a cross ‐sectional baseline analysis in general practice
Conclusion: We found an encouraging improvement compared to previous studies in the utilisation of antithrombotic therapy for stroke prevention in AF within general practice. Warfarin is now utilised as the mainstay therapy, followed by aspirin, although the novel oral anticoagulants are entering the spectrum of therapies used. Consideration needs to be given to the potential impact of the newer agents and their scope of use. There has been an encouraging temporal improvement in the utilization of antithrombotic therapy for stroke prevention in AF within general practice. Anticoagulants (mostly warfarin) are now utilized ...
Source: Journal of Clinical Pharmacy and Therapeutics - June 23, 2016 Category: Drugs & Pharmacology Authors: B. Bajorek, P. J. Magin, S. Hilmer, I. Krass Tags: Original Article Source Type: research

Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: meta ‐analysis by geographic region with a focus on European patients
ConclusionThe DOAC did not provide additional benefit in reducing the risk of stroke/SEE compared with warfarin in European patients with AF, but were generally associated with a lower bleeding tendency than warfarin regardless of geographic region.
Source: British Journal of Clinical Pharmacology - June 16, 2016 Category: Drugs & Pharmacology Authors: Antonio G ómez‐Outes, Ana‐Isabel Terleira‐Fernández, Gonzalo Calvo‐Rojas, M. Luisa Suárez‐Gea, Emilio Vargas‐Castrillón Tags: Systematic Review Source Type: research

Protective effects of cilostazol against hemorrhagic stroke: Current and future perspectives
Publication date: Available online 3 May 2016 Source:Journal of Pharmacological Sciences Author(s): Toshinori Takagi, Hideaki Hara Cilostazol is a phosphodiesterase-3 inhibitor and is known to have pleiotropic effects including antiplatelet and vasodilatation effects and protective effects on endothelial cells. Cilostazol also reportedly reduced stroke recurrence, poststroke intracranial hemorrhaging, and extracranial bleeding in a meta-analysis. Although it is known that cilostazol has the potential to suppress hemorrhagic stroke, the precise mechanisms remained unclear. Therefore, we evaluated the protective effects ...
Source: Journal of Pharmacological Sciences - June 15, 2016 Category: Drugs & Pharmacology Source Type: research

Decision-making around antithrombotics for stroke prevention in atrial fibrillation: the health professionals’ views
Conclusion The decision-making process appears to be partially preference based rather than systematic, and health professionals from various disciplines focus on different parts of the decision-making process.
Source: International Journal of Clinical Pharmacy - June 9, 2016 Category: Drugs & Pharmacology Source Type: research

Fimasartan: A New Angiotensin Receptor Blocker
Abstract Fimasartan is the ninth, and most recent, angiotensin II receptor antagonist approved as an antihypertensive agent. Fimasartan, a pyrimidin-4(3H)-one derivative of losartan with the imidazole ring replaced, which enables higher potency and longer duration than losartan. Fecal elimination and biliary excretion are the predominant elimination pathways of fimasartan and the urinary excretion was found to be less than 3 % 24 h after administration. Fimasartan is primarily catabolized by cytochrome P450 isoform 3A and no significant drug interaction was observed when used in combination with hydrochlorothia...
Source: Drugs - June 6, 2016 Category: Drugs & Pharmacology Source Type: research

Medicines and Vegetable Oils as Hidden Causes of Cardiovascular Disease and Diabetes
Background: Positive associations have been observed between cardiovascular disease (CVD) and type 2 diabetes mellitus (DM), but their causal relationship has not been clarified. Nevertheless, guidelines from relevant medical societies recommend using cholesterol lowering medication (statin) for both types of patients. Medicines with several different action mechanisms have been developed, and the effectiveness of different lifestyle modifications has been studied extensively for the prevention of DM, which was successful in improving clinical marker status in relatively short-term treatments, but none have been shown to b...
Source: Pharmacology - June 1, 2016 Category: Drugs & Pharmacology Source Type: research